A drug made by Boehringer Ingelheim and Zealand Pharma helped people lose 16.6% of their body weight in a late-stage trial (a big test before the FDA decides whether to approve a medicine). This is positive news for the companies' weight-loss drug program.

• •Boehringer-Zealand drug delivered 16.6% weight loss in late-stage trial
• •Trial is Phase 3 (pre-FDA decision stage)

Boehringer Ingelheim's survodutide, a dual-action drug that targets two hormones (glucagon and GLP-1) to help with weight loss, showed people lost an average of 16.6% of their body weight in a late-stage trial. The drug also improved other measures of metabolic health in people with obesity or excess weight.

• •Survodutide delivered 16.6% weight loss in Phase 3 obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, partnered with Zealand
• •Trial showed metabolic improvements in people with obesity or overweight

Boehringer Ingelheim announced that survodutide, a dual-action drug that works like both glucagon and GLP-1 (weight-loss hormones), helped people lose 16.6% of their body weight in a Phase III trial (a large late-stage test). The drug also improved other health markers related to metabolism in people with obesity or excess weight.

• •Survodutide hit 16.6% weight loss in Phase III obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim
• •Trial showed metabolic improvements in obesity/overweight patients

• •Boehringer's dual-acting obesity shot met its endpoint in a Phase 3 trial

Boehringer Ingelheim's survodutide, a GLP-1 dual agonist (a type of weight-loss and diabetes drug), showed positive results in a large Phase 3 trial (a major test required before FDA approval). The company is advancing the drug toward regulatory approval based on these successful trial results.

• •Boehringer Ingelheim's survodutide hit positive results in a Phase 3 trial
• •Survodutide is a GLP-1/glucagon dual agonist for weight loss and diabetes
• •Company advancing the drug toward regulatory approval

Boehringer Ingelheim and Zealand Pharma's obesity drug showed results in a Phase 3 trial (a late-stage test) that resembled Novo Nordisk's Wegovy (a popular weight-loss medicine). The comparison suggests the drug may be competitive in the weight-loss market.

• •Boehringer/Zealand obesity drug posted Phase 3 results compared to Novo's Wegovy
• •Trial profile described as 'more akin' to Wegovy

Boehringer Ingelheim's retatrutide, a dual-action weight-loss drug, helped people lose up to 16.6% of their body weight in a trial. Retatrutide works on two hormones in the body to reduce hunger and help with obesity.

• •Boehringer Ingelheim's dual agonist drove up to 16.6% body weight loss in a trial
• •The drug acts on two hormones to reduce hunger and treat obesity